Document is current
Any future updates will be listed below
-
Authors
Fox, Daniel https://orcid.org/0000-0003-0271-2776
Mathur, Anukriti https://orcid.org/0000-0002-7004-301X
Xue, Yansong
Liu, Yunqi
Tan, Wei Hong
Feng, Shouya
Pandey, Abhimanu
Ngo, Chinh
Hayward, Jenni A.
Atmosukarto, Ines I.
Price, Jason D.
Johnson, Matthew D.
Jessberger, Nadja
Robertson, Avril A. B. https://orcid.org/0000-0002-9652-8357
Burgio, Gaetan https://orcid.org/0000-0002-7434-926X
Tscharke, David C. https://orcid.org/0000-0001-6825-9172
Fox, Edward M.
Leyton, Denisse L.
Kaakoush, Nadeem O.
Märtlbauer, Erwin https://orcid.org/0000-0003-3390-8173
Leppla, Stephen H.
Man, Si Ming https://orcid.org/0000-0002-5079-2857
- License Information
-
More Information
Article History
Received: 3 August 2019
Accepted: 14 January 2020
First Online: 6 February 2020
Competing interests
: I.I.A. declares that they are director of Lipotek, a biotech company focused on liposome technology. I.I.A. and J.D.P. declare that they are shareholders of Lipotek. A.A.B.R. declares that they are a named inventor on inflammasome inhibitor patents (WO2018215818, WO2017140778, and WO2016131098). The other authors declare no competing interests.
